In a substudy of the Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) phase 2b trial, 240 patients with type 2 diabetes and CKD underwent 24-h ABPM. Here, NR3C2 is linked to chronic kidney disease.